



Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes

Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker, MD; Israel Shetboun, MD; Yuval Konstantino, MD; David Luria, MD; Natalie Gevriellov-Yusim, MSc; Ilan Goldenberg, MD; and Michael Glikson, MD. On behalf of the Israeli Working Group on Pacing and Electrophysiology.



BACKGROUND

- The ICD guidelines apply to both men and women, however,
- gender differences currently exist in the rate of utilization of ICDs.
- Men are 3 times more likely to receive a device for primary prevention and more than twice for secondary prevention
- A recent meta-analysis found no survival benefit for ICDs in women with heart failure and primary prevention indication



AIM


- To compare
 - The indication for ICD implantation
 - The type of ICD implanted
 - The re-intervention rate
 - outcomes

In women vs. men



METHODS

- The Israeli ICD registry is a prospective nationwide database of all ICD implants.
- All ICDs implants 7/2010-6/2012
- Web based CRF at implant / re-do procedure
- Follow up cohort centers interrogated
 - Median FU time ~ 12 months
 - Centers compliance rate ~ 50%



RESULTS


- Baseline cohort 2811 subjects (17% women)

N (%)	Women N=485	Men N=2326	p- value
Age mean \pm SD	64 \pm 13	65 \pm 12	0.14
Diabetes	156 (32)	871 (38)	0.02
Hypertension	275 (57)	1484 (64)	<0.01
Dyslipidemia	237 (49)	1301 (56)	<0.01
Smoking	60 (13)	819 (36)	<0.01





RESULTS

N (%)	Women N=485	Men N=2326	p- value
Ischemic cardiomyopathy	229 (47)	1862 (80)	<0.01
Severe LV dysfunction (LVEF<30%)	271 (59)	1253 (54)	<0.01
Atrial fibrillation	102 (21)	493 (21)	0.91
Heart failure; NYHA class			<0.01
I - II	177 (45)	1018 (55)	
III - IV	217 (55)	841 (45)	





RESULTS






RESULTS






RESULTS

Prevention Indication




Among 2ndry prevention:




■ SECONDARY ■ PRIMARY


■ VF



RESULTS


Device Type







Predictors of CRT (vs. ICD) Implantation (HR, 95%CI)

	All patients	
Gender women vs. men	2.4 (1.5-4.0)	
NYHA class 3 vs. 1-2	7.7 (6.2-9.7)	
QRS duration > 120 ms	10.8 (8.6-13.5)	
Left ventricular ejection fraction < 30% vs. higher	2.4 (1.8-3.1)	
Secondary vs. primary prevention indication	0.5 (0.4-0.7)	
Age	1.02 (1.01-1.03)	
GFR ≤60 ml/min vs. higher	1.3 (1.0-1.7)	



Re-intervention Rates






The Impact of Gender on Events during Follow up

	HR	95% CI	p-value
Death	0.98	0.40-2.41	0.96
Appropriate therapy	0.72	0.25 – 2.05	0.53
Heart failure admission	0.87	0.43-1.79	0.71
Death or appropriate therapy	0.87	0.44-1.72	0.69
Death or heart failure admission	0.92	0.42-1.530.	0.78




Time to Appropriate Therapy/ Death

Primary Prevention




Secondary Prevention






Time to HF admission / Death

ICD



CRTD





Conclusions

- Significant sex differences were found: women have
 - A higher proportion of non-ischemic cardiomyopathy.
 - A higher proportion of CRTS devices.
 - A higher rate of VF among the secondary prevention group.
- There are different factors associated with implantation of CRTD devices in men and women.



Conclusions

- Women have a higher rate of re-intervention procedures
- During follow up, there were no significant differences in the rate of:
 - Appropriate therapy
 - Heart failure admissions
 - Death
 - A combination of the above